Abstract
The article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.
Data obtained from patients with early RA suggest that serum triglycerides, a proxy of disease activity as markers of systemic inflammation, impaired function of apolipoprotein A-I and HDL particles, and mediating hypertension are determinants of the excess cardiovascular risk. These changes seem to be preceded by a lowering of total cholesterol and are followed in the course of the disease by immune processes typically illustrated by positivity of rheumatoid factor. Evidence is available to postulate the notion that reduced plasma lipoprotein- associated phospholipaseA2 mass or activity, mediated by diminished hydrolysis of VLDL triglycerides and of Lp(a) phospholipids, may induce reduction or altered composition of HDL particles and apoA-I dysfunction which, along with elevated plasma triglycerides, initiate and contribute to chronic inflammation.
Lifestyle modification, traditional non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors, low-dose corticosteroids, statins, tumor-necrosis-α inhibitors and, particularly, the immunosuppressive methotrexate, all have potential beneficial effects in eliciting a reduction in disease activity and cardiovascular risk. Adherence to the recent EULAR recommendations is a key in the prevention and management of cardiovascular risk among patients with rheumatic diseases.
Keywords: Anti-TNF therapy, cardiovascular diseases, disease-modifying anti-rheumatic drugs, HDL dysfunction, inflammation, lipoprotein(a), rheumatoid arthritis, syssystemic lupus erythematosus (SLE), ankylosing spondylitis, rheumatoid factor
Current Pharmaceutical Design
Title: Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Volume: 18 Issue: 11
Author(s): Altan Onat*Haner Direskeneli
Affiliation:
- Department of Cardiology, Cerrahpa,Turkey
Keywords: Anti-TNF therapy, cardiovascular diseases, disease-modifying anti-rheumatic drugs, HDL dysfunction, inflammation, lipoprotein(a), rheumatoid arthritis, syssystemic lupus erythematosus (SLE), ankylosing spondylitis, rheumatoid factor
Abstract: The article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.
Data obtained from patients with early RA suggest that serum triglycerides, a proxy of disease activity as markers of systemic inflammation, impaired function of apolipoprotein A-I and HDL particles, and mediating hypertension are determinants of the excess cardiovascular risk. These changes seem to be preceded by a lowering of total cholesterol and are followed in the course of the disease by immune processes typically illustrated by positivity of rheumatoid factor. Evidence is available to postulate the notion that reduced plasma lipoprotein- associated phospholipaseA2 mass or activity, mediated by diminished hydrolysis of VLDL triglycerides and of Lp(a) phospholipids, may induce reduction or altered composition of HDL particles and apoA-I dysfunction which, along with elevated plasma triglycerides, initiate and contribute to chronic inflammation.
Lifestyle modification, traditional non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors, low-dose corticosteroids, statins, tumor-necrosis-α inhibitors and, particularly, the immunosuppressive methotrexate, all have potential beneficial effects in eliciting a reduction in disease activity and cardiovascular risk. Adherence to the recent EULAR recommendations is a key in the prevention and management of cardiovascular risk among patients with rheumatic diseases.
Export Options
About this article
Cite this article as:
Onat Altan *, Direskeneli Haner, Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy, Current Pharmaceutical Design 2012; 18 (11) . https://dx.doi.org/10.2174/138161212799504740
DOI https://dx.doi.org/10.2174/138161212799504740 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism The Therapeutic Potential of Induced Pluripotent Stem Cells After Stroke: Evidence from Rodent Models
Current Stem Cell Research & Therapy Echocardiography Parameters in Behcet’s Disease, A Comparative Study
Current Rheumatology Reviews Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry
Current Alzheimer Research Acute Toxicological and Histopathological Elucidation of <i>Rheum emodi</i> Rhizome Extract to Demonstrate Antidiabetic Activity in Alloxan-induced Diabetic Rats
Current Bioactive Compounds From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design ENaC and Its Regulatory Proteins as Drug Targets for Blood Pressure Control
Current Drug Targets Microbial / Enzymatic Synthesis of Chiral Intermediates for Pharmaceuticals: Case Studies from BMS
Current Organic Chemistry Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Current Pharmaceutical Design Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design